Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint.

Literature DB >> 7082758

Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint.

Abstract

This paper presents nomograms for calculating the sample size for a clinical trial with survival as an endpoint. The nomograms are valid when survival is exponential and patients enter the study uniformly.

Entities: Species

Mesh：

Year: 1982 PMID： 7082758

Source DB: PubMed Journal: Biometrics ISSN： 0006-341X Impact factor: 2.571

Keyword Cloud
Cited

56 in total

1. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients.

Authors: Jing-Ting Jiang; Yue-Ping Shen; Chang-Ping Wu; Yi-Bei Zhu; Wen-Xiang Wei; Lu-Jun Chen; Xiao Zheng; Jing Sun; Bin-Feng Lu; Xue-Guang Zhang
Journal: World J Gastroenterol Date: 2010-12-28 Impact factor: 5.742

2. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen)

Authors: M Lorenz; H H Müller; H Schramm; H J Gassel; H G Rau; K Ridwelski; J Hauss; R Stieger; K W Jauch; W O Bechstein; A Encke
Journal: Ann Surg Date: 1998-12 Impact factor: 12.969

3. Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma.

Authors: Johannes E A Wolff; Sabine Wagner; Christiane Reinert; Astrid Gnekow; R-D Kortmann; Joachim Kühl; Stefaan W Van Gool
Journal: J Neurooncol Date: 2006-04-28 Impact factor: 4.130

4. The first multicenter, randomized, controlled trial of home telemonitoring for Japanese patients with heart failure: home telemonitoring study for patients with heart failure (HOMES-HF).

Authors: Norihiko Kotooka; Masafumi Kitakaze; Kengo Nagashima; Machiko Asaka; Yoshiharu Kinugasa; Kotaro Nochioka; Atsushi Mizuno; Daisuke Nagatomo; Daigo Mine; Yoko Yamada; Akiko Kuratomi; Norihiro Okada; Daisuke Fujimatsu; So Kuwahata; Shigeru Toyoda; Shin-Ichi Hirotani; Takahiro Komori; Kazuo Eguchi; Kazuomi Kario; Takayuki Inomata; Kaoru Sugi; Kazuhiro Yamamoto; Hiroyuki Tsutsui; Tohru Masuyama; Hiroaki Shimokawa; Shin-Ichi Momomura; Yoshihiko Seino; Yasunori Sato; Teruo Inoue; Koichi Node
Journal: Heart Vessels Date: 2018-02-15 Impact factor: 2.037

5. Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424.

Authors: Barbara J Fisher; Chen Hu; David R Macdonald; Glenn J Lesser; Stephen W Coons; David G Brachman; Samuel Ryu; Maria Werner-Wasik; Jean-Paul Bahary; Junfeng Liu; Arnab Chakravarti; Minesh Mehta
Journal: Int J Radiat Oncol Biol Phys Date: 2015-01-30 Impact factor: 7.038

6. High-Dose Vitamin D₃ during Tuberculosis Treatment in Mongolia. A Randomized Controlled Trial.

Authors: Davaasambuu Ganmaa; Baatar Munkhzul; Wafaie Fawzi; Donna Spiegelman; Walter C Willett; Purev Bayasgalan; Erkhembayar Baasansuren; Burneebaatar Buyankhishig; Sereeter Oyun-Erdene; David A Jolliffe; Theodoros Xenakis; Sabri Bromage; Barry R Bloom; Adrian R Martineau
Journal: Am J Respir Crit Care Med Date: 2017-09-01 Impact factor: 21.405

7. Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations.

Authors: Lu Tian; Haoda Fu; Stephen J Ruberg; Hajime Uno; Lee-Jen Wei
Journal: Biometrics Date: 2017-09-12 Impact factor: 2.571

8. Sample size and power for a logrank test and Cox proportional hazards model with multiple groups and strata, or a quantitative covariate with multiple strata.

Authors: John M Lachin
Journal: Stat Med Date: 2013-05-13 Impact factor: 2.373

9. Effects of Personalized Feedback Interventions on Drug-Related Reoffending: a Pilot Study.

Authors: Kenji Yokotani; Katsuhiro Tamura
Journal: Prev Sci Date: 2015-11

10. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer.

Authors: S Negoro; N Masuda; Y Takada; T Sugiura; S Kudoh; N Katakami; Y Ariyoshi; Y Ohashi; H Niitani; M Fukuoka
Journal: Br J Cancer Date: 2003-02-10 Impact factor: 7.640